SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VPHM - Viropharma Inc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (114)7/14/1999 7:22:00 PM
From: moby_dick  Respond to of 2557
 
Well Richard, we'll just have to agree to disagree on the points you mention. I believe today's prices are based almost solely on the fact that the public thought this company had a "cure for the common cold." When they find out otherwise, the stock price will go back down from whence it came IMO. If the target is indeed meningitis then I think it might be fairly valued at at 50% premium over where the price was a few days ago - $8 + $4 = $12 - anything more is pure hype at this point.

Good luck
Moby.



To: scaram(o)uche who wrote (114)7/14/1999 8:05:00 PM
From: Anthony@Pacific  Respond to of 2557
 
Rarely do I run across someone who tries so hard to sound informed , yet fails to make even one factual point or valid argument...This stock is doomed to single digits within a very short period of time ...Youargument about applying to the FDA is countered by VPHM's own SEC filings ..they know that they are about to go under..why else do you think all the hype is coming on now


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News